C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016

  • ID: 3775409
  • Drug Pipelines
  • 77 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • Cytodyn Inc.
  • GlaxoSmithKline Plc
  • NeED Pharma s.r.l.
  • Pharis Biotec GmbH
  • Tobira Therapeutics, Inc.
  • MORE
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016

Summary

‘C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016’, provides in depth analysis on C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5)
- The report reviews C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • Cytodyn Inc.
  • GlaxoSmithKline Plc
  • NeED Pharma s.r.l.
  • Pharis Biotec GmbH
  • Tobira Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) Overview

Therapeutics Development

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Stage of Development

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Therapy Area

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Indication

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Products Glance

Late Stage Products

Early Stage Products

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Companies

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development

American Gene Technologies International Inc.

ChemoCentryx, Inc.

Cytodyn Inc.

GlaxoSmithKline Plc

NeED Pharma s.r.l.

Pharis Biotec GmbH

Tobira Therapeutics, Inc.

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles

(cenicriviroc mesylate + efavirenz + lamivudine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cenicriviroc mesylate + lamivudine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-1105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAL-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAL-MGMT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAL-X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCL-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-214096 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-4043 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRO-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RAP-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Dormant Projects

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Featured News & Press Releases

May 16, 2016: Clinical Abstract from CytoDyn’s PRO 140 Phase 2b HIV Monotherapy Trial Now Available on ASM Microbe 2016 Conference Website

May 13, 2016: Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients

May 03, 2016: CytoDyn’s Compassionate Use Protocol Receives FDA Clearance to Proceed

May 02, 2016: Tobira Announces Interim 12-week Results from the ORION Study

Apr 14, 2016: CytoDyn Files a Compassionate Use Protocol With FDA

Mar 09, 2016: Tobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials

Feb 09, 2016: Tobira Therapeutics Completes Patient Recruitment for ORION Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease

Jan 28, 2016: CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months

Jan 22, 2016: CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy

Jan 20, 2016: CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer

Jan 19, 2016: CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy

Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis

Dec 22, 2015: CytoDyn Files for Orphan Drug Designation for Use of PRO 140 in Graft Versus Host Disease

Dec 21, 2015: FDA Clears CytoDyn for Relaxed Entry Criteria for Its Ongoing Phase 3 Trial in HIV-Infected Patients

Dec 14, 2015: CytoDyn Receives FDA Clearance for Its First Non-HIV Indication for PRO 140

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by American Gene Technologies International Inc., H1 2016

Pipeline by ChemoCentryx, Inc., H1 2016

Pipeline by Cytodyn Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by NeED Pharma s.r.l., H1 2016

Pipeline by Pharis Biotec GmbH, H1 2016

Pipeline by Tobira Therapeutics, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • Cytodyn Inc.
  • GlaxoSmithKline Plc
  • NeED Pharma s.r.l.
  • Pharis Biotec GmbH
  • Tobira Therapeutics, Inc.
  • MORE
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) C-X-C chemokine receptor type 5 (CXC-R5) also known as CD185, is a G protein-coupled receptor for chemokine CXCL13. It plays an important role in B-cell migration into B-cell follicles of spleen and Peyer patches. It plays a regulatory function in Burkitt lymphoma (BL) lymphomagenesis and/or B-cell differentiation.

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Our latest report C-C Chemokine Receptor Type 5 – Pipeline Review, H1 2016, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
American Gene Technologies International Inc.
ChemoCentryx, Inc.
Cytodyn Inc.
GlaxoSmithKline Plc
NeED Pharma s.r.l.
Pharis Biotec GmbH
Tobira Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll